Ensign Peak Advisors
RCUS icon

Ensign Peak Advisors’s Arcus Biosciences RCUS Stock Holding History

Ensign Peak Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.65M Sell
215,613
-37,320
-15% -$922K 0.01% 512
2026
Q1 		$5.46M Buy
+252,933
New +$5.46M 0.01% 512
2022
Q4 		– Sell
-9,880
Closed -$258K – 2125
2022
Q3 		$258K Hold
9,880
– – ﹤0.01% 1773
2022
Q2 		$250K Hold
9,880
– – ﹤0.01% 1728
2022
Q1 		$312K Hold
9,880
– – ﹤0.01% 1736
2021
Q4 		$400K Buy
+9,880
New +$383K ﹤0.01% 1704
2021
Q1 		– Sell
-15,972
Closed -$415K – 1875
2020
Q4 		$415K Sell
15,972
-1,774
-10% -$42.9K ﹤0.01% 1635
2020
Q3 		$304K Buy
+17,746
New +$396K ﹤0.01% 1616

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Ensign Peak Advisors's RCUS Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Arcus Biosciences (RCUS) stake by 15% in Q2 2026, selling an estimated $922K and leaving 215,613 shares worth $6.65M. The position accounts for 0.01% of the portfolio, ranked #512.

Ensign Peak Advisors first reported a position in RCUS in Q3 2020 and has held it in 8 quarters since. 232 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Ensign Peak Advisors held 215,613 shares of Arcus Biosciences worth $6.65M as of Q2 2026.
  • Ensign Peak Advisors sold 37,320 Arcus Biosciences shares in Q2 2026, an estimated $922K.
  • Arcus Biosciences made up 0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #512 holding.
  • Ensign Peak Advisors first reported a position in Arcus Biosciences in Q3 2020 and has held it in 8 quarters since.
  • 232 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.